Mechanistic Target of Rapamycin (mTOR) Inhibitors.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary clinical data
PubMed 35091825 · doi:10.1007/164_2021_553
What was done
This is a narrative review describing the mechanism of action, FDA-approved indications, adverse effect profiles, and therapeutic applications of mechanistic target of rapamycin (mTOR) inhibitors (including sirolimus, everolimus, and temsirolimus) in transplantation and oncology.
What was found
The abstract reports no quantitative data or statistical comparisons. It outlines that mTOR inhibitors block downstream cytokine signal transduction to induce cell cycle arrest at the G1-to-S phase. It details FDA approvals for sirolimus (renal transplantation, lymphangioleiomyomatosis), everolimus (advanced HR+/HER2- breast cancer, pancreatic neuroendocrine tumors, advanced renal cell carcinoma, renal angiomyolipoma, tuberous sclerosis complex-associated subependymal giant cell astrocytoma, and renal/liver transplantation), and temsirolimus (advanced renal cell carcinoma).
Why it matters
It provides a consolidated summary of the clinical pharmacology, FDA-approved indications, and therapeutic mechanisms of mTOR inhibitors across transplant medicine and cancer management.
Limits
The record is a descriptive narrative overview without original clinical trial data, a systematic literature search protocol, or quantitative synthesis of drug efficacy and adverse event rates relative to comparator regimens.
Cited by
- supports Sirolimus (rapamycin) is FDA-approved for the prevention of organ transplant rejection.